Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) saw an uptick in trading volume on Thursday following a better than expected earnings announcement. 1,014,430 shares traded hands during trading, an increase of 195% from the previous session’s volume of 343,499 shares.The stock last traded at $5.25 and had previously closed at $5.25.

The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 180.85%. The business’s revenue for the quarter was up 400.3% on a year-over-year basis.

Several brokerages recently weighed in on PIRS. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Pieris Pharmaceuticals in a report on Friday. BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Four analysts have rated the stock with a buy rating, Pieris Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $9.00.

In related news, insider Allan Reine acquired 65,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were bought at an average price of $4.82 per share, with a total value of $313,300.00. Following the completion of the acquisition, the insider now owns 45,000 shares in the company, valued at $216,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James A. Geraghty acquired 10,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, for a total transaction of $48,200.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $48,200. The disclosure for this purchase can be found here. 4.05% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN acquired a new stake in Pieris Pharmaceuticals during the third quarter worth approximately $105,000. JPMorgan Chase & Co. purchased a new position in shares of Pieris Pharmaceuticals during the third quarter worth approximately $600,000. New York State Common Retirement Fund grew its position in shares of Pieris Pharmaceuticals by 107.5% during the third quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 17,100 shares during the last quarter. First Quadrant L P CA purchased a new position in shares of Pieris Pharmaceuticals during the third quarter worth approximately $473,000. Finally, California State Teachers Retirement System purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $308,000. 50.87% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals, Inc. (PIRS) Sees Large Volume Increase on Earnings Beat” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/pieris-pharmaceuticals-inc-pirs-sees-large-volume-increase-on-earnings-beat/1694679.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.